US Patent

US11235168 — Method of photodynamic therapy (PDT) for bladder cancer

Method of Use · Assigned to Photocure ASA · Expires 2038-01-04 · 12y remaining

Vulnerability score 70/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects a method of photodynamic therapy for bladder cancer using a composition instilled into the bladder and exposed to blue light.

USPTO Abstract

This invention relates to a method of photodynamic therapy (PDT) for bladder cancer and its use as an adjuvant or neoadjuvant therapy in the treatment of bladder cancer. The invention provides a composition comprising hexyl 5-ALA ester (HAL) or a pharmaceutically acceptable salt thereof for use in a method of photodynamic therapy for bladder cancer, wherein said composition is instilled into the bladder of a patient in need of such treatment and the inside of said bladder is exposed to blue light having a fluence rate of 1.5 to 12.5 mW/cm2.

Drugs covered by this patent

hexaminolevulinate-hydrochloride (HEXAMINOLEVULINATE HYDROCHLORIDE)

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-2250`	—	hexaminolevulinate-hydrochloride

Patent Metadata

Patent number: US11235168
Jurisdiction: US
Classification: Method of Use
Expires: 2038-01-04
Drug substance claim: No
Drug product claim: No
Assignee: Photocure ASA
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.